Johnson & Johnson Agrees to Pay Up to $5.5 Billion to Settle Talc Lawsuits
By Elias Schisgall
Johnson & Johnson agreed to pay up to $5.5 billion to resolve remaining lawsuits that alleged the company's talc products caused ovarian cancer.
The company said Monday that it had reached an agreement with firms representing plaintiffs in the outstanding talc cases. The agreement is conditioned on 95% of remaining claimants participating, Johnson & Johnson said.
The company also said that the plaintiffs had acknowledged they wouldn't be able to meet a standard of "specific causation": that Johnson & Johnson's talc products explicitly caused any individual claimant's ovarian cancer.
Johnson & Johnson said it would pay up to $3 billion in claim payments in 2027 under the agreement, with no further payments due before 2028. It committed $5.5 billion to claim payments in total.
Shares of Johnson & Johnson rose 1.9%, to $270.88, in after-hours trading Monday.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
July 27, 2026 18:59 ET (22:59 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for October
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
The Thrilling 37
3 Stocks to Invest In With More Room to Run
United States